Corticosteroids (CS)

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, ITB-Med LLC, Seoul National University

Conditions

Kidney TransplantationNSCLC, Non Small Cell Lung Cancer

Phase 1

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

CompletedNCT02217410

Novartis PharmaceuticalsKidney Transplantation

Start: 2015-02-05End: 2017-11-29Updated: 2021-09-28

Phase 2

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

CompletedNCT03663335

Novartis PharmaceuticalsKidney Transplantation

Start: 2018-11-28End: 2021-10-29Updated: 2026-03-23

A Dose Escalation Study in de Novo Renal Transplantation

CompletedNCT04311632

ITB-Med LLCKidney Transplantation

Start: 2021-05-26End: 2023-10-03Updated: 2025-02-27

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

TerminatedNCT06365437

ITB-Med LLCKidney Transplantation

Start: 2021-06-06End: 2024-12-11Updated: 2026-03-12

Unknown Phase

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active, not recruitingNCT06751108

Seoul National UniversityNSCLC, Non Small Cell Lung Cancer

Start: 2024-11-01End: 2025-06-30Target: 2000Updated: 2024-12-27

Related Papers

CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients

Transplantation2018-07-019 citations